Cipla

Cipla has been co-marketing Vildagliptin in agreement with Novartis under brand names Vysov and Vysov M (Vildagliptin plus…

On the BSE, the stock hit intra-day high of Rs 476.35, up 1.83 per cent. It settled 0.22 per cent up at Rs 468.80. On the BSE, the…

Cipla (EU) already has a 60 per cent stake in Cipla Pharma Lanka Pvt Ltd. Post-acquisition, Cipla Pharma Lanka will become a…

The acquisition is aimed at further strengthening the firm's presence in branded Indian critical care space, and as a part of its…

The single-dose vials are for intravenous use only

Following an inspection by USFDA at the company’s API manufacturing facility in Virgonagar, from July 15 to 19, the company has…

Under this agreement, Cipla will get the exclusive marketing rights for five years in India for DFU product with Stempeutics…

As opportunities in developed markets saturate, India Pharma Inc is looking to optimise the growth potential in China. But what…

The paediatric palliative care unit will cater to children with all life-limiting and life-threatening conditions treated at the…

The Chinese pharma market is set to be worth $209 billion by 2022 Indian pharmaceutical companies are finding lucrative…